ERBB2 and breast cancer: Of these, Huang et al. divided all patients into groups based on receptor status, with ER-positive or -negative groups [23], and Jadaliha et al. did not report a negative result in all patients but mentioned the survival outcomes in the lymph node-negative TNBC and HER2-positive breast cancer subsets [24].